Disturbances in core body temperature in RIP140-null mice

Journal of Thermal Biology

Volumn 34, Issue 2, 2009, Pages 100-108

  Hudson Davies, R ^a   Pocock, V ^a   White, R ^b   Parker, M ^b   Milligan, S R ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Activity; Anxiety; Brown adipose tissue; Core body temperature; Nrip1; RIP140; Telemetry; Thermoregulation

Indexed keywords

EID: 59649116269     PISSN: 03064565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtherbio.2008.11.003     Document Type: Article

References (50)

1. Augustsson H., Dahlborn K., and Meyerson B.J. Exploration and risk assessment in female wild house mice (Mus musculus) and two laboratory strains. Physiol. Behav. 84 (2005) 265-277
2. Bligh J. A theoretical consideration of the means whereby the mammalian core temperature is defended at a null zone. J. Appl. Physiol. 100 (2006) 1332-1337
3. Cannon B., and Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol. Rev. 84 (2004) 277-359
4. Casas F., Pessemesse L., Grandemange S., Seyer P., Gueguen N., Baris O., Lepourry L., Cabello G., and Wrutniak-Cabello C. Overexpression of the mitochondrial T3 receptor p43 induces a shift in skeletal muscle fiber types. PLoS ONE 3 (2008) e2501
5. Christian M., Kiskinnis E., Debevec D., Leonardsson G., White R., and Parker M.G. RIP140-targeted repression of gene expression in adipocytes. Mol. Cell Biol. 25 (2005) 9383-9391
6. Christian M., White R., and Parker M.G. Metabolic regulation by the nuclear receptor corepressor RIP140. Trends Endocrinol. Metab. 17 (2006) 243-250
7. Chuang F.M., West B.L., Baxter J.D., and Schaufele F. Activities in Pit-1 determine whether receptor interacting protein 140 activates or inhibits Pit-1/nuclear receptor transcriptional synergy. Mol. Endocrinol. 11 (1997) 1332-1341
8. Collinson N., and Dawson G.R. On the elevated plus-maze the anxiolytic-like effects of the 5-HT(1A) agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT(1A) partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635. Psychophamacology 132 (1997) 35-43
9. Commins S.P., Marsh D.J., Thomas S.A., Watson P.M., Padgett M.A., Palmiter R., and Gettys T.W. Norepinephrine is required for leptin effects on gene expression in brown and white adipose tissue. Endocrinology 140 (1999) 4772-4778
10. Debevec D., Christian M., Morganstein D., Seth A., Herzog B., Parker M., and White R. Receptor interacting protein 140 regulates expression of uncoupling protein 1 in adipocytes through specific peroxisome proliferator activated receptor isoforms and estrogen-related receptor. Mol. Endocrinol. 21 (2007) 1581-1592
11. Dulloo A.G. Regulation of fat storage via suppressed thermogenesis: a thrifty phenotype that predisposes individuals with catch-up growth to insulin resistance and obesity. Horm. Res. 65 (2006) 90-97
12. Gavrilova O., Marcus-Samuels B., and Reitman M.L. Lack of responses to a beta3-adrenergic agonist in lipoatrophic A-ZIP/F-1 mice. Diabetes 49 (2000) 1910-1916
13. Golozoubova V., Gullberg H., Matthias A., Cannon B., Vennstrom B., and Nedergaard J. Depressed thermogenesis but competent BAT recruitment in mice devoid of all hormone-binding thyroid hormone receptors. Mol. Endocrinol. 18 (2004) 384-401
14. Haim A., McDevitt R., and Speakman J. Daily variations in the response of wood mice Apodemus sylvaticus to noradrenaline. J. Exp. Biol. 198 (1995) 561-565
15. 2 consumption; opposite effects of leptin and etomoxir on respiratory quotient in mice. Obesity 14 (2006) 673-682
16. Jay M.A., and Ren J. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr. Diabetes Rev. 3 (2007) 33-39
17. Jurgens H.S., Schurmann A., Kluge R., Ortmann S., Klaus S., Joost H.-G., and Tscho M.H. Hyperphagia, lower body temperature, and reduced running wheel activity precede development of morbid obesity in New Zealand obese mice. Physiol. Genomics 25 (2006) 234-241
18. Kalaany N.Y., and Mangelsdorf D.J. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 68 (2006) 159-191
19. Kanizsai P., Garami A., Solymár M., Szolcsányi J., and Szelényi Z. Energetics of fasting heterothermia in TRPV1-KO and wild type mice. Physiol. Behav. (2008) [Epub ahead of print; doi:10.1016/j.physbeh.2008.09.023]
20. Kiskinis E., Hallberg M., Christian M., Olofsson M., Dilworth S.M., White R., and Parker M.G. RIP140 directs histone modifications and de novo DNA methylation activity to silence Ucp1 gene expression in white adipocytes. EMBO J. 26 (2007) 4831-4840
21. Koutnikova H., Cock T.-A., Watanabe M., Houten S.M., Champy M.-F., Dierich A., and Auwerx J. Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR hypomorphic mice. PNAS 100 (2003) 14457-14462
22. Landsberg L. A teleological view of obesity, diabetes and hypertension. Clin. Exp. Pharmacol. Physiol. 9 (2006) 863-867
23. Lee C.H., Chinpaisal C., and Wei L.N. Cloning and characterization of mouse RIP140, a corepressor for nuclear orphan receptor TR2. Mol. Cell Biol. 18 (1998) 6745-6755
24. Lee C.H., Olson P., and Evans R.M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144 (2003) 2201-2207
25. Leon L.R., Walker L.D., Dubose D.A., and Stephenson L.A. Biotelemetry transmitter implantation in rodents: impact on growth and circadian rhythms. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286 (2004) R967-R974
26. Leonardsson G., Jacobs M.A., White R., Jeffery R., Poulson R., Milligan S., and Parker M. Embryo transfer experiments and ovarian transplantation identify the ovary as the only site in which nuclear receptor interacting protein 1/RIP140 action is crucial for female fertility. Endocrinology 143 (2002) 700-707
27. Leonardsson G., Steel J.H., Christian M., Pocock V., Milligan S., Bell J., So P.W., Medina-Gomez G., Vidal-Puig A., White R., and Parker M.G. Nuclear receptor corepressor RIP140 regulates fat accumulation. Proc. Natl. Acad. Sci. USA 101 (2004) 8437-8442
28. Levine J.A., Lanningham-Foster L.M., McCrady S.K., Krizan A.C., Olson L.R., Kane P.H., Jensen M.D., and Clark M.M. Interindividual variation in posture allocation: possible role in human obesity. Science 307 (2005) 584-586
29. L'Horset F., Dauvois S., Heery D.M., Cavailles V., and Parker M.G. RIP-140 interacts with multiple nuclear receptors by means of two distinct sites. Mol. Cell Biol. 16 (1996) 6029-6036
30. Lim H.J., Moon I., and Han K. Transcriptional cofactors exhibit differential preference toward peroxisome proliferator-activated receptors α and δ in uterine cells. Endocrinology 145 (2005) 2886-2895
31. Marrif H., Schifman A., Stepanyan Z., Gillis M.A., Calderone A., Weiss R.E., Samarut J., and Silva J.E. Temperature homeostasis in transgenic mice lacking thyroid hormone receptor-alpha gene products. Endocrinology 146 (2005) 2872-2884
32. McKenna N.J., Lanz R.B., and O'Malley B.W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 20 (1999) 321-344
33. Mochizuki T., Klerman E.B., Sakurai T., and Scammell T.E. Elevated body temperature during sleep in orexin knockout mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291 (2006) R533-R540
34. Morrow J.D., and Opp M.R. Diurnal variation of lipopolysaccharide-induced alterations in sleep and body temperature of interleukin-6-deficient mice. Brain Behav. Immun. 19 (2005) 40-51
35. Muoio D.M., and Koves T.R. Skeletal muscle adaptation to fatty acid depends on coordinated actions of the PPARs and PGC1 alpha: implications for metabolic disease. Appl. Physiol. Nutr. Metab. 32 (2007) 874-883
36. Powelka A.M., Seth A., Virbasius J.V., Kiskinis E., Nicoloro S.M., Guilherme A., Tang X., Straubhaar J., Cherniack A.D., Parker M.G., and Czech M.P. Suppression of oxidative metabolism and mitochondrial biogenesis by the transcriptional corepressor RIP140 in mouse adipocytes. J. Clin. Invest. 116 (2006) 125-136
37. Puigserver P. Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha. International Journal of Obesity 29 Suppl. 1 (2005) S5-S9
38. Puri V., Virbasius J.V., Guilherme A., and Czech M.P. RNAi screens reveal novel metabolic regulators: RIP140, MAP4k4 and the lipid droplet associated fat specific protein (FSP) 27. Acta Physiol. (Oxf.) 192 (2008) 103-115
39. Ravussin E. Physiology. A NEAT way to control weight?. Science 307 (2005) 530-531
40. Seth A., Steel J.H., Nichol D., Pocock V., Kumaran M.K., Fritah A., Mobberley M., Ryder T.A., Rowlerson A., Scott J., Poutanen M., White R., and Parker M. The transcriptional corepressor RIP140 regulates oxidative metabolism in skeletal muscle cell metabolism. Cell Metab. 6 (2007) 236-245
41. Shulman A.I., and Mangelsdorf D.J. Retinoid X receptor heterodimers in the metabolic syndrome. N. Eng. J. Med. 353 (2005) 604-615
42. Steel J.H., White R., and Parker M.G. Role of the RIP140 corepressor in ovulation and adipose biology. J. Endocrinol. 185 (2005) 1-9
43. Tang X., and Sanford L.D. Telemetric recording of sleep and home cage activity in mice. Sleep 25 (2002) 691-699
44. Treuter E., Albrektsen T., Johansson L., Leers J., and Gustafsson J.A. A regulatory role for RIP140 in nuclear receptor activation. Mol. Endocrinol. 12 (1998) 864-881
45. Wang H., Zhang Y., Yehuda-Shnaidman E., Medvedev A.V., Kumar N., Daniel K.W., Robidoux J., Czech M.P., Mangelsdorf D.J., and Collins S. Liver X receptor alpha is a transcriptional repressor of the uncoupling protein 1 gene and the brown fat phenotype. Mol. Cell Biol. 28 (2008) 2187-2200
46. Watanabe T., Hashimoto M., Okuyama S., Inagami T., and Nakakmura S. Effects of targeted disruption of the mouse angiotensin II type 2 receptor gene on stress-induced hyperthermia. J. Physiol. 515 (1999) 881-885
47. White R., Leonardsson G., Rosewell I., Ann Jacobs M., Milligan S., and Parker M. The nuclear receptor corepressor nrip1 (RIP140) is essential for female fertility. Nat. Med. 6 (2000) 1368-1374
48. Yamauchi T., Kamon J., Waki H., Murakami K., Motojima K., Komeda K., Ide T., Kubota N., Terauchi Y., Tobe K., Miki H., Tsuchida A., Akanuma Y., Nagai R., Kimura S., and Kadowaki T. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem. 276 (2001) 41245-41254
49. Yen P.M. Physiological and molecular basis of thyroid hormone action. Physiol. Rev. 81 (2001) 1097-1142
50. Zuther, P., Lemmer, B., 2004. last update, chronos-fit [Homepage of University of Heidelberg, Germany], [Online]. Available: 〈http://www.ma.uni-heidelberg.de/inst/phar/forschungLemmer.html〉 [10/12, 2004].